Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia.
Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia.
复制标题
CLL-1 低表达是 123 名新发 CD34 急性髓系白血病患者的新不良预测因子。
DOI：
10.1089/scd.2016.0310
复制
发表时间：
2017-10
影响因子：
4
通讯作者：
Jin Wang
中科院分区：
文献类型：
--
作者：
Yan-Yu Wang;Wen-Lian Chen;Xiang-Qin Weng;Yan Sheng;Jing Wu;Jie Hao;Zhan-Yun Liu;Yong-Mei Zhu;Bing Chen;Shu-Min Xiong;Yu Chen;Qiu-Sheng Chen;Hui-Ping Sun;Jun-Min Li;Jin Wang
近年来的研究表明，C型凝集素样分子-1（CLL-1）在急性髓系白血病（AML）中主要表达于髓系细胞，但其对白血病原始细胞的预后意义尚未见报道。因此，本研究旨在评估CLL-1在123例新发CD 34+非M3 AML患者中的预后价值。采用多参数流式细胞术检测AML和对照组未成熟区室中CLL-1的表达。我们发现CLL-1在原始细胞室的表达水平与患者的临床特征、治疗反应和生存结局密切相关。急性髓细胞白血病患者未成熟区室中CLL-1的表达明显低于对照组（62.6% vs.86.5%，P < 0.05）。Logistic模型显示CLL-1低独立预测低完全缓解率，OR为4.57（2.53-6.61，P < 0.05）。此外，CLL-1在诊断时的表达水平与诱导化疗后残留的原始细胞（残留白血病细胞）呈负相关（r =-0.423，P < 0.05）。多因素考克斯回归模型显示CLL-1低仍是独立的不良预测因子（P < 0.05，无事件生存期; P < 0.05，总生存期）。值得注意的是，CLL-1 low能够将生存不良的患者与中等和可接受的风险组区分开来。总之，CLL-1是一种新的预后预测因子，可用于补充目前的AML预后风险分层系统，并可能优化AML的临床管理。
Recent reports state that C-type lectin-like molecule-1 (CLL-1) in acute myeloid leukemia (AML) is expressed primarily on myeloid cells, but there is still no investigation about its prognostic significance on leukemic blast compartment. Hence, this study aimed to evaluate the prognostic value of CLL-1 in 123 patients with de novo CD34+ Non-M3 AML. Multiparameter flow cytometry was used to assess the expression of CLL-1 on immature compartment in AML and control groups. We found that CLL-1 expression level on blast compartment was closely linked to clinical characteristics, treatment response, and survival outcome of patients. Decreased expression of CLL-1 was observed on immature compartment from AML patients as compared with controls (62.6% vs. 86.5%, P < 0.05). Logistic model exhibited that CLL-1low independently predicted low complete remission rate with an odds ratio of 4.57 (2.53-6.61, P < 0.05). Additionally, CLL-1 expression level at diagnosis was inversely correlated to the residual blast cells (residual leukemia cell) after induction chemotherapy (r = -0.423, P < 0.05). Furthermore, multivariate Cox regression model demonstrated that CLL-1low was still an independent adverse predictor (P < 0.05 for event-free survival, P < 0.05 for overall survival). Notably, CLL-1low was able to discriminate poor survival patients from intermediate- and favorable-risk groups. Taken together, CLL-1 is a novel prognostic predictor that could be exploited to supplement the current AML prognostic risk stratification system, and potentially optimize the clinical management of AML.
登录
查看更多内容
影响因子：
7.7
作者：
Chiba S;Ikushima H;Ueki H;Yanai H;Kimura Y;Hangai S;Nishio J;Negishi H;Tamura T;Saijo S;Iwakura Y;Taniguchi T
通讯作者：
Taniguchi T
DOI：
10.1007/978-3-030-73227-1_13
发表时间：
2021
期刊：
Practical Oncologic Molecular Pathology
影响因子：
--
作者：
Guang Yang;Linsheng Zhang
通讯作者：
Guang Yang;Linsheng Zhang
通过髓样C型凝集素受体传感细胞死亡。
影响因子：
7
作者：
Sancho D;Reis e Sousa C
通讯作者：
Reis e Sousa C
影响因子：
3.7
作者：
Sattler, S.;Ghadially, H.;Hofer, E.
通讯作者：
Hofer, E.
影响因子：
16.6
作者：
Lu, Hua;Zhou, Quan;Deshmukh, Vishal;Phull, Hardeep;Ma, Jennifer;Tardif, Virginie;Naik, Rahul R.;Bouvard, Claire;Zhang, Yong;Choi, Seihyun;Lawson, Brian R.;Zhu, Shoutian;Kim, Chan Hyuk;Schultz, Peter G.
通讯作者：
Schultz, Peter G.